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1. Introduction 
Epilepsy is the second commonest chronic neurological disorder in developed countries with 
an estimated prevalence of around 9.7 per 1000 population and an incidence of 0.55 per 1000 
per year.[1] Other United Kingdom studies have suggested a prevalence of 7.7 per 1000 
population and 5.6 per 1000 population.[2 3] There is a consistent association between 
epilepsy and socioeconomic status with a higher prevalence and incidence in the less 
affluent.[2] People with epilepsy are known to have more physical ill-health than the general 
population, but previous studies examining this have not usually accounted for higher rates of 
socioeconomic deprivation in people with epilepsy and have studied less comorbidities.[3-5] 
Lower socioeconomic status is also strongly associated with multimorbidity, with people 
living in the most deprived areas having more multimorbidity than those living in the most 
affluent areas, and on average developing multimorbidity 10-15 years earlier.[6] The 
observed association between epilepsy and the presence of other conditions may therefore 
partly or entirely reflect that people with epilepsy are less affluent.  
Mental illness, particularly depression, is also commonly recognised in people with epilepsy, 
and rates of depression and anxiety are higher than in the general population.[7] A recent 
large cohort study concluded there was a bidirectional relationship between epilepsy and 
depression and the authors proposed that a common neurobiology to account for the 
association.[8] An alternative explanation however is that higher prevalence of depression in 
people with epilepsy reflects the increasing burden of deprivation and physical ill health and 
that they suffer and this is not unique to epilepsy but occurs with many other chronic 
illnesses.   
The aim of this study was to compare the prevalence of comorbid physical and mental health 
conditions in those with and without epilepsy aged 14 and over after accounting for age, 
gender and social deprivation, and to examine the prevalence of depression in people with 
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epilepsy compared to people with other physical conditions after accounting for the total 
burden of comorbid physical disease.  
2. Methods 
The design was secondary analysis of a cross-sectional analysis of an established database for 
1,510,742 people aged 14 and over who were registered with 314 primary care practices in 
Scotland, United Kingdom on 31st March 2007. The original dataset was created for a study 
of the epidemiology of multimorbidity, and counted 40 common physical and mental health 
conditions including epilepsy.  
The UK National Health Service (NHS) requires registration with a single primary care 
practice, and 98% of people in Scotland are registered with a general practice. All Scottish 
general practices use electronic medical records, and the record is transferred between 
practices when people move. The data covers approximately one third of the Scottish 
population, and has previously been shown to be representative of the whole Scottish 
population in terms of age, sex and socioeconomic deprivation.[9] In the UK National Health 
Service (NHS), epilepsy is diagnosed in secondary care by a specialist who writes to the 
patient’s general practitioner who then records the diagnosis in the medical record. The 
medical record belongs to the NHS and when patients move their record follows them, 
meaning that a lifelong primary care record exists.  
People were defined as having epilepsy if their record included a Read Code for epilepsy 
recorded ever AND they had been prescribed an antiepileptic drug (AED) in the last 12 
months.[10] The full case definition is included in appendix 1, and matches that of ‘active 
epilepsy’ used in the UK Quality and Outcomes Framework programme which incentivises 
practices to maintain disease registers for selected conditions including epilepsy.[11] The 
focus of the study was on people aged 14 years of age and above since this is the approximate 
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age at which people with epilepsy begin to be transferred to adult services in the UK 
(although the actual age of transition varies by locality and, reflecting national guidance, may 
involve joint clinics for adolescents).[12] 
Data on 31 other common and important physical conditions and 8 mental health conditions 
were also extracted as described in previous publications, although these were defined in 
relation to the original study rather than pre-specified as being relevant to epilepsy (appendix 
2).[6] Finally, data on age, sex, and socioeconomic status measured using the Carstairs’ 
deprivation score were extracted. The Carstairs’ score is a measure of neighbourhood 
socioeconomic deprivation assigned to individuals based on their postcode of residence, and 
has been widely used in healthcare research.[13 14] 
The characteristics of people with and without epilepsy were compared in terms of sex, age, 
socioeconomic status measured by quintiles (equal fifths of the Scottish population) of the 
Carstairs score, and the number of comorbid conditions they had. The prevalence of the 31 
physical conditions in people with and without epilepsy was then compared, using both 
unadjusted and adjusted prevalence odds ratios (pOR). Adjustment was carried out using a 
logistic regression model with the presence or absence of the comorbid condition as the 
binary outcome variable, and adjusted for characteristics including age, sex and deprivation. 
The same analysis was carried out for the prevalence of the eight comorbid mental health 
conditions, but the number of physical conditions (excluding epilepsy) was included in the 
adjustment, reflecting that physical disease burden is known to be strongly associated with 
the presence of depression in particular.[6 15] Data was analysed using SPSS version 22 and 
differences tested for statistical significance using t-tests assuming unequal variances for 
continuous data and chi-squared tests and confidence intervals for the difference between 
proportions for categorical variables. The NHS Grampian Research Ethics Service had 
previously approved the anonymous use of these data for research purposes.   
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3. Results   
Of the 1,510,742 people included in the dataset, 12,720 had epilepsy (prevalence 8.4 per 
1000 population, 95% CI 8.3 to 8.5). The prevalence of epilepsy rose with age from 4.9 per 
1000 in 14 to 24 year olds to a peak of 10.3 per 1000 in 65 to 84 years, falling slightly to 8.4 
per 1000 in people aged 85 years and over. There was a social gradient in prevalence, rising 
from 6.4 per 1000 in people living in the most affluent fifth of areas to 10.7 per 1000 for 
those living in the most deprived. 69.9% of people with epilepsy had one or more of the 39 
other conditions examined, compared to 46.9% of the general population who did not have 
epilepsy. People with epilepsy had a mean of 0.81 (95% CI 0.78 to 0.85, p<0.001) more 
comorbid conditions than people without, with 1.02 (95% CI 0.99 to 1.06, p<0.001) more 
physical and 0.26 (95% CI 0.25 to 0.27, p<0.001) more mental health conditions. (Table 1). 
Of the comorbid physical health conditions 29 out of 31 had statistically significantly 
increased unadjusted odds of occurring in people with epilepsy compared to people without 
epilepsy. After adjustment for differences in age, gender and deprivation the number of 
statistically significantly increased odds ratios fell to 24 of the 31 comorbid physical health 
conditions studied. The strongest adjusted associations were with constipation (prevalence 
OR [pOR] 4.83 for prevalence in people with epilepsy compared to those without), stroke or 
transient ischaemic attack (TIA) (pOR 4.58), blindness (pOR 3.38), chronic liver disease 
(pOR 2.57) and migraine (pOR 2.36). Of the two conditions with statistically significantly 
lower crude prevalence in people with epilepsy, adjustment for age, sex and deprivation 
rendered the association with chronic sinusitis non-significant (adjusted pOR 0.90, 95% CI 
0.71 to 1.14) whereas the association with hypertension remained statistically significant but 
clinically small (adjusted pOR 0.94, 95% CI 0.89 to 0.99).(Table 2).  
All eight of the mental health conditions studied were more common in people with epilepsy, 
and these associations remained statistically significant after adjustment for deprivation, age 
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and gender, and after additionally adjusting for number of physical health conditions. The 
strongest association was with the presence of learning disabilities (adjusted pOR 29.1, 95% 
CI 27.1 to 31.3 for people with epilepsy vs those without). Depression was the most prevalent 
mental health condition for people with and without epilepsy, but occurred significantly more 
often in people with epilepsy (16.3% vs 9.5%, unadjusted pOR 1.85, 95% CI 1.77 to 1.82; 
fully adjusted pOR 1.57, 95% CI 1.49 to 1.65) (Table 3).  
The prevalence of comorbid depression in people with epilepsy rose steadily with both the 
number of comorbid physical conditions and with increasing socioeconomic deprivation 
(Figure 1). These relationships persisted after adjustment in a logistic regression model for 
age, sex as well as the number of physical conditions and deprivation (adjusted pOR for 
depression for those with four or more physical comorbidities vs none 5.82, 95% CI 4.90 to 
6.91; and for the most deprived vs the most affluent of 1.51, 95% CI 1.27 to 1.79). Similar 
patterns of increasing prevalence of comorbid depression with increasing physical 
comorbidity were seen for a range of other physical conditions, with the prevalence of 
depression given the presence of other physical disease not strikingly different for epilepsy 
than other conditions. (Figure 2). 
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4. Discussion 
This study found that people with epilepsy have more other physical and mental health 
conditions than the general population even after adjusting for age, gender and 
socioeconomic deprivation. Over two-thirds of people with epilepsy had at least one other of 
the 39 conditions examined, and almost one in five had four or more other conditions. The 
associations between epilepsy and the presence of all the mental health conditions examined 
were weakened by adjustment for age, gender, deprivation and physical ill health, but 
remained statistically and are usually clinically significant. The prevalence of depression in 
people with epilepsy increased with increasing levels of physical comorbidity and 
deprivation, and the strength of association for the same total burden of physical disease and 
deprivation was similar to that observed for people with a number of other chronic physical 
conditions including asthma, coronary heart disease, chronic obstructive pulmonary disease, 
peripheral vascular disease and diabetes.  
Many of the somatic and psychiatric associations identified within this study can be 
explained by biologically plausible mechanisms proposed in previous studies. These state that 
the association is likely to reflect a direct causal association, an example of shared genetic or 
environmental factors, or a result of epilepsy and its treatment. It is well established that 
stroke is a cause of epilepsy, particularly for large infarcts. 23% of all epilepsy over the age 
of 65 and almost 10% overall is considered to be secondary to cerebrovascular disease.[16] 
The association between epilepsy and other structural brain disorders has been identified in 
previous studies, notably for multiple sclerosis and Parkinson’s Disease,[17-19]and 
neurodegenerative disorders are believed to account for 25% of all epilepsy in older 
people.[16] Epilepsy secondary to another pathology is the probable explanation of why 
people with epilepsy are older than people without epilepsy in this study.  
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Migraine has also been consistently associated with epilepsy and this is likely to reflect 
common genetic and environmental factors.[20 21] Epilepsy and a number of other 
conditions may also share a common aetiology. For example, alcohol dependency is 
commonly associated with epilepsy, peptic ulcer disease and chronic liver disease. Some 
conditions are likely to result from adverse effects of both epilepsy and or its treatment such 
as the association with dermatological disorders (although genetic factors clearly contribute) 
and constipation.[22 23] The association between epilepsy and depression has led to interest 
in whether a common neurobiological mechanism may predispose to both.[4 7] Although the 
cross-sectional nature of this study does not allow direct exploration of causality, the finding 
that the prevalence of depression is similar in epilepsy as the prevalence in many chronic 
physical health conditions with disparate aetiologies is consistent with depression being 
significantly driven by the experience of chronic ill health and stigma in addition to any 
common neurobiological mechanism unique to epilepsy and depression.[24-27] Additionally, 
the prevalence of depression in people with epilepsy is strongly associated with an increasing 
physical comorbidity burden, again consistent with the experience of chronic ill health being 
a significant driver of depression. This study cannot examine this directly because it is cross-
sectional, but the only large longitudinal study in this area found that the association between 
epilepsy and depression is bidirectional (people with epilepsy are at a higher risk of 
depression and vice versa).[8] Further longitudinal studies of this would be helpful.  
A strength of this study is the method by which people with active epilepsy were selected to 
only include people coded as having epilepsy who were receiving current drug treatment. 
This ensures that those with a historical diagnosis of epilepsy who were no longer taking 
medication were excluded. A limitation is that like all such routine data studies, this study is 
reliant on the accuracy of clinical coding. At the time of data extraction, general practices 
were financially incentivised to create and maintain an accurate register of people with 
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epilepsy, and this was subject to external audit and inspection.[28 29] The prevalence of 
epilepsy in this study (8.4 per 1000) was higher than the 5.6 per 1000 found in an older study 
using similar UK primary care electronic medical record data from before epilepsy registers 
were incentivised.[3] A recent population study using data linkage techniques and a validated 
gold standard cohort found a similar prevalence (7.7 per 1000, CI 7.6 to 7.9),[2] and 
previously it has been suggested that the prevalence of epilepsy is 9.7 per 1000 increasing 
confidence in the completeness of recording.[1] However, a limitation is that like other cross-
sectional routine data studies, GP registers do not accurately record type of epilepsy, and it is 
only possible to examine associations rather than directly explore causality.[30] Routine data 
studies of comorbidity could also be subject to a type of surveillance bias, in that people with 
epilepsy may attend primary care more often than the general population, resulting in the 
increased identification of comorbidities.[31 32] However, this proposition is not supported 
by studies using direct methods of case ascertainment such as household surveys. For 
example, a Canadian population study relying on household surveys also found higher 
prevalence of comorbidity in people with epilepsy compared to general population 
controls.[5] 
The frequency of comorbid conditions in epilepsy highlights the need for increased vigilance 
within primary and secondary care. A finding that almost 50% of people with epilepsy have 
multiple comorbidities highlights the complexity faced by the primary care physician who is 
expected to manage such comorbidity without compromising seizure control, and by 
specialists who will need to account for important comorbidities when deciding on treatment. 
This is particularly important because comorbid epilepsy and mental health conditions are 
associated with reduced quality of life and increased mortality.[33 34] The reason for this 
remains unclear but commonly used medications for mood disorders, anxiety and psychosis 
such as tricyclic antidepressants, selective serotonin reuptake inhibitors and antipsychotics 
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are known to potentially lower the “seizure threshold”.[35 36] Concerns about psychotrophic 
medication reducing seizure threshold could also potentially lead to poorly treated depression 
which would contribute to observed lower quality of life in people with epilepsy and 
comorbid mental health conditions.[34] The evidence provided highlights that those with 
epilepsy are potentially challenging to primary care physicians who are faced with the 
complex balance between seizure control and treating comorbid conditions which can 
potentially lead to inadequate treatment for associated mental illness.  
Given the socioeconomic patterning of epilepsy, this highlights the importance of equitable 
access to primary care a strength currently found in the United Kingdom healthcare system. 
In addition, adequate funding for the training and retention of primary care physicians with a 
special interest in common chronic health conditions (“the expert generalist”) including 
epilepsy may provide a solution to managing this complex group within a community setting, 
although further research is required to determine the optimum management of this group of 
patients.[37-40] 
5. Conclusion 
This study demonstrates that those with epilepsy have greater levels of comorbidity than the 
general population but the influence that comorbidity and poly-pharmacy have on outcome 
remains unclear. Research in well-described population clinical cohorts is needed to 
determine the relative importance of intrinsic factors (epilepsy type, genetics, significant 
clinical factors) and external factors (such as comorbidity, polypharmacy, and socioeconomic 
status), to inform the development of stratified health care to be applied to those with 
complex epilepsy.  
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Table 1: Characteristics of people aged 14 years and over with and without epilepsy in the 
dataset 
 People with epilepsy 
(≥14 years) 
No. (%) 
N=12720 
People without 
epilepsy (≥14 years) 
No. (%) 
N=1498022 
Prevalence of epilepsy 
Prevalence per 1000 
population (95% CI) 
Sex 
Male 
Female 
 
6415 (50.4) 
6305 (49.6) 
 
737567 (49.2) 
760455 (50.8) 
 
8.6 (8.4 to 8,8) 
8.2 (8.0 to 8.4) 
Age Group (years) 
14 to 24 
25 to 44 
45 to 64 
65 to 84 
85 and over 
          
1171 (9.2) 
3918 (30.8) 
4701 (37.0) 
2623 (20.6) 
307 (2.4) 
 
236886 (15.8) 
504471 (33.7) 
468426 (31.3) 
251977 (16.8) 
36262 (2.4) 
 
4.9 (4.6 to 5.2) 
7.7 (7.5 to 7.9) 
9.9 (9.6 to 10.2) 
10.3 (9.9 to 1.1) 
8.4 (7.5 to 9.4) 
Deprivation (quintiles) 
Q1 (least deprived) 
Q2 
Q3 
Q4 
Q5 (most deprived) 
 
1852 (14.6) 
2356 (18.5) 
2897 (22.8) 
2728 (21.4) 
2887 (22.7) 
 
286337 (19.1) 
320417 (21.4) 
338906 (22.6) 
285080 (19.0) 
267282 (17.8) 
 
6.4 (6.1 to 6.7) 
7.3 (7.0 to 7.6) 
8.5 (8.2 to 8.8) 
9.5 (9.2 to 9.9) 
10.7 (10.3 to 11.1) 
   Difference in % with 
comorbidity (95% CI) 
No. of comorbidities 
None  
One  
Two 
Three 
Four or more 
 
3824 (30.1) 
2939 (23.1) 
2105 (16.5) 
1482 (11.7) 
2370 (18.6) 
 
794708 (53.1) 
308679 (20.6) 
162848 (10.9) 
97196 (6.5) 
134591 (9.0) 
  
-23.0 (-22.2 to -23.8) 
 2.5 (1.8 to 3.2) 
 5.7 (5.0 to 6.3) 
 5.2 (4.6 to 5.7) 
 9.6 (9.0 to 10.3) 
No. of physical 
comorbidities 
None 
One  
Two 
Three  
Four or more 
 
 
5093 (40.0) 
3174 (25.0) 
1895 (14.9) 
1166 (9.2) 
1392 (10.9) 
 
 
874288 (58.4) 
299187 (20.0) 
147627 (9.9) 
82638 (5.5) 
94282 (6.3) 
 
 
-18.3 (-17.5 to -19.2) 
 5.0 (4.2 to 5.7) 
 5.0 (4.4 to 5.7) 
 3.6 (3.2 to 4.2) 
 4.6 (4.1 to 5.2) 
No. of mental health 
comorbidities 
None 
One 
Two 
Three or more 
 
 
8428 (66.3) 
3280 (25.8) 
840 (6.6) 
172 (1.4) 
 
 
1280682 (85.5) 
181406 (12.1) 
30901 (2.1) 
5033 (0.3) 
 
 
-19.2 (-18.4 to -20.1) 
13.7 (12.9 to 14.5) 
4.5 (4.1 to 5.0) 
1.0 (0.8 to 1.2) 
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Table 2: Prevalence of comorbid physical conditions in people with and without epilepsy 
Physical 
Condition 
People with 
epilepsy 
No. (%) 
N=12720 
People without 
epilepsy No. 
(%) 
N=1498022 
Unadjusted 
Prevalence OR 
(95% CI) 
Adjusted for age,  
sex, deprivation  
Prevalence OR 
(95% CI) 
Constipation 1317 (10.4) 35302 (2.4) 4.79 (4.52 to 5.07) 4.83 (4.54 to 5.15) 
Stroke or TIA 1245 (9.8) 35328 (2.4) 4.49 (4.23 to 4.77) 4.58 (4.29 to 4.89) 
Blindness 268 (2.1) 8430 (0.6) 3.80 (3.36 to 4.30) 3.38 (2.99 to 3.83) 
Chronic liver disease 67 (0.5) 2547 (0.2) 3.11 (2.44 to 3.97) 2.57 (2.02 to 3.28) 
Migraine 187 (1.5) 9319 (0.6) 2.38 (2.06 to 2.76) 2.36 (2.04 to 2.73) 
Multiple sclerosis 73 (0.6) 3777 (0.3) 2.28 (1.81 to 2.88) 2.23 (1.77 to 2.82) 
Viral hepatitis 19 (0.1) 1157 (0.1) 1.94 (1.23 to 3.05) 1.83 (1.16 to 2.88) 
Parkinson’s disease 48 (0.4) 2695 (0.2) 2.10 (1.58 to 2.80) 1.82 (1.36 to 2.43) 
Dyspepsia (treated) 1247 (9.8) 78128 (5.2) 1.98 (1.86 to 2.10) 1.77 (1.67 to 1.88) 
Pain 1845 (14.5) 124456 (8.3) 1.87 (1.78 to 1.97) 1.65 (1.57 to 1.74) 
Bronchiectasis 41 (0.3) 2798 (0.2) 1.73 (1.27 to 2.35) 1.53 (1.12 to 2.08) 
Psoriasis or eczema 144 (1.1) 10570 (0.7) 1.61 (1.37 to 1.90) 1.50 (1.27 to 1.77) 
Deafness 756 (5.9) 55940 (3.7) 1.63 (1.51 to 1.75) 1.45 (1.35 to 1.57) 
Thyroid disorders 880 (6.9) 71267 (4.8) 1.49 (1.39 to 1.59) 1.41 (1.32 to 1.52) 
Heart Failure 243 (1.9) 18667 (1.2) 1.54 (1.36 to 1.75) 1.33 (1.17 to 1.52) 
Asthma (currently treated) 998 (7.8) 90557 (6.0) 1.32 (1.24 to 1.41) 1.32 (1.24 to 1.41) 
COPD 678 (5.3) 53224 (3.6) 1.53 (1.41 to 1.65) 1.29 (1.19 to 1.40) 
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Coronary heart disease 987 (7.8) 80484 (5.4) 1.48 (1.39 to 1.58) 1.26 (1.17 to 1.35) 
Glaucoma 191 (1.5) 15741 (1.1) 1.44 (1.24 to 1.66) 1.25 (1.08 to 1.45) 
New diagnosis of cancer 
diagnosis in last 5 years 
512 (4.0) 43428 (2.9) 1.41 (1.29 to 1.54) 1.24 (1.14 to 1.36) 
Irritable bowel syndrome 547 (4.3) 51908 (3.5) 1.25 (1.15 to 1.36) 1.23 (1.13 to 1.34) 
Atrial fibrillation 280 (2.2) 23699 (1.6) 1.40 (1.24 to 1.58) 1.22 (1.08 to 1.38) 
Inflammatory bowel disease 103 (0.8) 9721 (0.6) 1.25 (1.03 to 1.52) 1.19 (0.98 to 1.44) 
Peripheral vascular disease 267 (2.1) 23063 (1.5) 1.37 (1.21 to 1.55) 1.16 (1.02 to 1.31) 
Diabetes 814 (6.4) 74515 (5.0) 1.31 (1.22 to 1.40) 1.12 (1.04 to 1.20) 
Diverticular disease 338 (2.7) 33482 (2.2) 1.19 (1.07 to 1.33) 1.05 (0.94 to 1.18) 
Prostate 168 (1.3) 15067 (1.0) 1.29 (1.11 to 1.51) 1.05 (0.89 to 1.23) 
Chronic kidney disease 324 (2.5) 33243 (2.2) 1.15 (1.03 to 1.29) 1.01 (0.90 to 1.14) 
Hypertension 2199 (17.3) 232156 (15.5) 1.14 (1.09 to 1.19) 0.94 (0.89 to 0.99) 
Rheumatoid arthritis, other 
inf. poly-arthropathies 
including gout and systemic 
connective tissue disorders 
518 (4.1) 57810 (3.9) 1.06 (0.97 to 1.16) 0.93 (0.85 to 1.01) 
Chronic sinusitis 72 (0.6) 9139 (0.6) 0.93 (0.74 to 1.17) 0.90 (0.71 to 1.14) 
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Table 3: Prevalence of comorbid mental health conditions in people with and without epilepsy 
Mental People with 
epilepsy No. 
(%) 
N=12720 
People without 
epilepsy 
No. (%) 
N=1498022 
Unadjusted 
Prevalence OR 
(95% CI) 
Adjusted for age 
sex and deprivation 
Prevalence OR 
(95% CI) 
Adjusted for age, sex, 
deprivation and number 
of physical conditions 
(excluding epilepsy) 
Prevalence OR (95% 
CI) 
Learning disability 
 
995 (7.8) 4147 (0.3) 30.6 (28.5 to 32.8) 30.5 (28.4 to 32.8) 29.1 (27.1 to 31.3) 
Dementia 
 
266 (2.1) 11441 (0.8) 2.78 (2.45 to 3.14) 2.83 (2.48 to 3.22) 2.77 (2.43 to 3.16) 
Anxiety and other 
neurotic, stress related and 
somatoform disorders 
1255 (9.9) 54764 (3.7) 2.89 (2.72 to 3.06) 2.64 (2.49 to 2.81) 2.40 (2.26 to 2.56) 
Alcohol problem 
 
979 (7.7) 41660 (2.8) 2.92 (2.73 to 3.11) 2.58 (2.41 to 2.76) 2.44 (2.28 to 2.61) 
Schizophrenia and related 
non-organic psychosis or  
bipolar disorder 
262 (2.1) 12238 (0.8) 2.55 (2.26 to 2.89) 2.36 (2.09 to 2.67) 2.29 (2.03 to 2.60) 
Other psychoactive 
substance misuse 
832 (6.5) 41754 (2.8) 2.44 (2.27 to 2.62) 2.17 (2.02 to 2.33) 1.96 (1.82 to 2.11) 
Anorexia or bulimia 
 
89 (0.7) 5311 (0.4) 1.98 (1.61 to 2.44) 2.15 (1.74 to 2.65) 1.99 (1.61 to 2.46) 
Depression 
 
2067 (16.3) 142182 (9.5) 1.85 (1.77 to 1.94) 1.73 (1.65 to 1.82) 1.57 (1.49 to 1.65) 
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Figure 1: Prevalence of comorbid depression in people with epilepsy by the number of comorbid physical conditions and socioeconomic deprivation
 
Figure 2: Prevalence of comorbid depression in people with epilepsy and other index conditions 
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